ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities

Ren, Anqi; Tong, Xiqin; Xu, Na; Zhang, Tongcun; Zhou, Fuling*; Zhu, Haichuan*武汉大学
Vaccines2023-1DOI: 10.3390/vaccines11010165
7被引5阅读
引用收藏
分享

摘要

T-cell acute lymphoblastic leukemia (T-ALL), a form of T-cell malignancy, is a typically aggressive hematological malignancy with high rates of disease relapse and a poor prognosis. Current guidelines do not recommend any specific treatments for these patients, and only allogeneic stem cell transplant, which is associated with potential risks and toxicities, is a curative therapy. Recent clinical trials showed that immunotherapies, including monoclonal antibodies, checkpoint inhibitors, and CAR T therapies, are successful in treating hematologic malignancies. CAR T cells, which specifically target the B-cell surface antigen CD19, have demonstrated remarkable efficacy in the treatment of B-cell acute leukemia, and some progress has been made in the treatment of other hematologic malignancies. However, the development of CAR T-cell immunotherapy targeting T-cell malignancies appears more challenging due to the potential risks of fratricide, T-cell aplasia, immunosuppression, and product contamination. In this review, we discuss the current status of and challenges related to CAR T-cell immunotherapy for T-ALL and review potential strategies to overcome these limitations.

学科与关键词

关键词
immunotherapyT-ALLCAR TfratricideT-cell aplasiaproduct contamination
相关
加载中…
  • Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
    Xu, Xinjie; Huang, Shengkang; Xiao, Xinyi; Sun, Qihang; Liang, Xiaoqian; Chen, Sifei; Zhao, Zijing; Huo, Zhaochang; Tu, Sanfang*; Li, Yuhua*Frontiers in Immunology, 2021, 11: 569117.被引 29
  • Current state of CAR-T therapy for T-cell malignancies
    Luo, Liangkui; Zhou, Xuan; Zhou, Lijuan; Liang, Zhao; Yang, Jilong; Tu, Sanfang*; Li, Yuhua*Therapeutic Advances in Hematology, 2022, 13: 20406207221143025.被引 6
  • T-ALL Cells as Tool Cells for CAR T Therapy
    Ren, Anqi; Zhao, Yuan; Zhu, Haichuan*Vaccines, 2023, 11(4): 854.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Vaccines
发表日期
2023-01
卷期
第 11 卷, 第 1 期
页码
165
DOI
10.3390/vaccines11010165
成果收录
SCIE

作者

  • R

    Ren, Anqi (第一作者)

    wuhan univ sci & technol

  • T

    Tong, Xiqin

    wuhan univ

查看全部 6 位作者收起作者
  • X

    Xu, Na

    wuhan univ sci & technol

  • Z

    Zhang, Tongcun

    tianjin univ sci & technol · wuhan univ sci & technol

  • Z

    Zhou, Fuling (通讯)

    wuhan univ sci & technol · wuhan univ

  • Z

    Zhu, Haichuan (通讯)

    wuhan univ sci & technol

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417